Logotype for Turnstone Biologics Corp

Turnstone Biologics (TSBX) investor relations material

Turnstone Biologics Q1 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Turnstone Biologics Corp
Q1 2025 earnings summary9 May, 2025

Executive summary

  • Discontinued all company-sponsored clinical studies, including TIDAL-01, and began exploring strategic alternatives in January 2025.

  • Workforce reduced to 8 employees as of March 31, 2025, with further reductions possible; cost-containment and cash conservation measures implemented.

  • Engaged a financial advisor to assist in the strategic review process, which may extend beyond Q2 2025.

  • Transferred listing from Nasdaq Global Market to Nasdaq Capital Market effective March 31, 2025, maintaining the TSBX ticker.

  • If no transaction is consummated, the board may pursue dissolution and liquidation, with cash available to stockholders dependent on timing and contingent liabilities.

Financial highlights

  • Net loss of $11.8 million for Q1 2025, compared to $19.6 million for Q1 2024, reflecting a 40% year-over-year improvement.

  • Operating expenses decreased to $9.2 million in Q1 2025 from $20.7 million in Q1 2024, primarily due to the shutdown of clinical development.

  • Cash, cash equivalents, and short-term investments totaled $21.9 million as of March 31, 2025, down from $28.9 million at December 31, 2024.

  • No revenue from product sales; accumulated deficit reached $259.4 million as of March 31, 2025.

  • Net loss per share was $0.51 for Q1 2025, compared to $0.85 for Q1 2024.

Outlook and guidance

  • Cash and cash equivalents expected to fund planned expenditures and obligations for at least 12 months from the financial statement filing date.

  • Actively evaluating a range of strategic alternatives to maximize shareholder value; further updates will be provided as appropriate.

  • Strategic review process is ongoing, with no assurance of a transaction or cash distributions to stockholders.

  • If a strategic transaction is not completed, dissolution and liquidation may be pursued.

Strategic alternatives impact on cash?
Why transfer to Nasdaq Capital Market?
What milestones trigger Myst payments?
Projected cash runway with current burn rate?
Update on strategic alternatives timeline?
Plan to meet Nasdaq listing requirements?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Turnstone Biologics Corp is a clinical-stage biotechnology company engaged in developing innovative therapies for patients with solid tumors. Their work is centered around the development of tumor infiltrating lymphocytes (TIL) therapies, with a specific focus on selecting and expanding potent tumor-reactive T cells to address the limitations of bulk TILs. Their pipeline includes TIDAL-01 and TIDAL-02, with TIDAL-01 being their lead selected TIL product candidate. This candidate utilizes an unbiased identification and functional screening process to isolate and expand a broad range of tumor-reactive TILs from a patient's tumor. The company is headquartered in La Jolla, California, and its shares are listed on the Nasdaq under the symbol TSBX.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage